【深圳商报讯】（记者李佳佳）日前，记者从深圳市市场监督管理局（知识产权局）获悉，深圳获国家 知识产权局批复，同意深圳市福田区开展国家级知识产权快速维权中心建设。 据透露，这是我市首家获批建设的国家级知识产权快速维权中心，按照相关要求完成建设任务并验收合 格后，将纳入全国知识产权快速协同保护工作机制，面向时尚设计产业开展知识产权快速维权工作。 深圳一直以来把知识产权作为创新驱动发展和优化营商环境的重要支撑，持续深化知识产权领域改革创 新，深入开展知识产权体系建设，在国家知识产权强市建设示范城市、国家知识产权保护高地"双示 范"建设中迈出坚实步伐。 知识产权保护中心和快速维权中心是国家知识产权保护体系的两大组成部分，是服务创新主体、优化营 商环境的重要力量。国家级知识产权快速维权中心聚焦外观设计、工业设计领域对于知识产权快速保护 的迫切需求，在相关产业优势聚集的地区重点开展知识产权快速确权、快速授权、快速维权等服务。 据了解，深圳福田（时尚设计）快维中心建成后，将使时尚设计相关产业外观设计专利授权时间大幅缩 短80%以上（外观设计专利授权时限最快1周），从"被动防御"到"主动护航"，通过打通绿色授权、维 权快车道 ...

Financial Data and Key Metrics Changes - The company reported net revenue of $52.5 million for Q1 2025, representing over 90% growth compared to Q1 2024, which had net revenue of $27.2 million [9][17] - Gross profit for Q1 2025 was $46.9 million, up from $25.7 million in the prior year [17] - The company raised its full-year revenue guidance to $255 million to $265 million from a previous range of $240 million to $260 million [17][9] - Cash operating expenses for Q1 2025 were reported at $44.9 million, a decrease of 3% year-over-year [20] Business Line Data and Key Metrics Changes - The company ended Q1 2025 with 2,800 patients on LUMRIZE, reflecting 100% growth year-over-year [8] - There was a 50% increase in net new patients during Q1 compared to Q4 2024, with an addition of 300 patients [8] - The sales force was increased by 15% effective January 1, 2025, contributing to positive patient demand growth across all segments [9][10] Market Data and Key Metrics Changes - The company is pursuing additional indications for LUMRIZE beyond narcolepsy, with a favorable court ruling allowing for further development [6][7] - The phase three REVITALIZE trial for idiopathic hypersomnia is on track, with expectations to complete enrollment by the end of 2025 [13] Company Strategy and Development Direction - The company aims to achieve $1 billion in LUMRIZE narcolepsy revenue while expanding its impact to other patient populations [16] - There is a focus on lifecycle management initiatives to maximize the potential of LUMRIZE beyond narcolepsy [23] - The company is also developing a once-nightly lower sodium oxybate program to serve patients with hypersomnia-related disorders [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth plan and the positive momentum seen in Q1 2025, expecting to build on this throughout the year [6][8] - The company remains focused on sustaining momentum and achieving sustainable positive cash flow [23] - Management highlighted the importance of their robust intellectual property portfolio, which protects LUMRIZE until 2042 [24] Other Important Information - The company ended Q1 2025 with $66.5 million in cash, cash equivalents, and marketable securities [21] - The company is actively pursuing legal actions against Jazz Pharmaceuticals to protect its business and intellectual property [15] Q&A Session Summary Question: Revised 2025 guidance and growth assumptions - Management confirmed that the first half of 2025 is expected to show sequential growth quarter-over-quarter, with a focus on improving key metrics [29][30] Question: Appeal case ruling implications - Management stated that the ruling was aligned with their base case scenario and provides a clear path to continue executing their plans [34][35] Question: Patient footprint potential for LUMRIZE in IH - Management views the IH opportunity as highly untapped and believes LUMRIZE can successfully source patients from various segments [39] Question: Average selling price and guidance - The average net revenue per patient was reported to be under $80,000 annualized, with expectations for improvement throughout the year [47][48] Question: Patient mix and persistency tactics - Management reported improvements in both switch and new to oxybate patients, with ongoing initiatives to enhance patient engagement and persistency [53][55] Question: Offensive lawsuits and timelines - Management elaborated on their offensive lawsuits against Jazz Pharmaceuticals, asserting their rights regarding intellectual property [83][84]

Financial Data and Key Metrics Changes - The company reported net revenue of $52.5 million for Q1 2025, representing over 90% growth compared to Q1 2024, which had net revenue of $27.2 million [7][18] - Gross profit for Q1 2025 was $46.9 million, up from $25.7 million in the prior year [18] - The company raised its full-year revenue guidance to $255 million to $265 million from a previous range of $240 million to $260 million [17][19] Business Line Data and Key Metrics Changes - The company ended Q1 with 2,800 patients on LUMRIZE, reflecting 100% growth year-over-year [6] - There was a 50% increase in net new patients during Q1 compared to Q4 2024, with an addition of 300 patients [6] - The company expanded its sales force by 15% and doubled the size of its field reimbursement and nursing support teams, contributing to improved patient engagement and persistency [8][9][10] Market Data and Key Metrics Changes - The company is pursuing additional indications for LUMRIZE beyond narcolepsy, particularly idiopathic hypersomnia (IH), with an estimated 42,000 patients diagnosed and only one FDA-approved treatment currently available [11][12] - The company believes LUMRIZE has the potential to unlock significant market opportunities in IH, as prescribers express excitement about the prospect of prescribing it for this condition [11][12] Company Strategy and Development Direction - The company aims to achieve $1 billion in LUMRIZE revenue while expanding its impact to additional patient populations [15] - The company is focused on lifecycle management initiatives to maximize the potential of its once-at-bedtime formulation beyond narcolepsy [23] - The company is actively pursuing legal actions to protect its intellectual property and has a robust portfolio that extends protection until 2042 [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the commercial investments made at the beginning of the year, which are expected to drive sustainable positive cash flow [23] - The company remains optimistic about its growth trajectory, despite potential industry-wide changes related to tariffs and policies impacting biotech [21] - Management highlighted the importance of maintaining financial discipline while scaling operations and expects continued revenue growth and cash flow improvement [19][20] Other Important Information - The company ended Q1 2025 with $66.5 million in cash, cash equivalents, and marketable securities [20] - The company reported a GAAP operating loss of $3 million for Q1, but adjusted operating income was positive at $2 million, marking the third consecutive quarter of positive adjusted operating income [20] Q&A Session Summary Question: Revised 2025 guidance and growth assumptions - Management confirmed that the first half of the year is expected to show sequential growth quarter over quarter, with a focus on improving key metrics [28][29] Question: Nature of the recent court ruling - Management indicated that the ruling was aligned with their base case scenario and provides a clear path to continue executing their plans for LUMRIZE [34][35] Question: Patient metrics and competitive landscape for IH - Management views the IH opportunity as highly untapped and believes LUMRIZE can successfully source patients from various segments, including those not currently treated with oxybate [40][41] Question: Discontinuation rates and updated guidance - Management reported a decrease in discontinuation rates from 14% in Q4 to a lower figure in Q1, contributing to increased confidence in their updated guidance [77][79] Question: Offensive lawsuits and timelines - Management elaborated on their offensive lawsuits against Jazz, asserting their intellectual property rights, and mentioned upcoming administrative steps in the litigation process [81][84]

Core Viewpoint - The protection of intellectual property is essential for technological innovation, and Hubei province has made significant progress in this area, with a focus on enhancing the legal framework and enforcement mechanisms to safeguard various types of intellectual property [1][2]. Group 1: Intellectual Property Protection Achievements - In 2024, Hubei's prosecutorial authorities arrested 284 individuals and prosecuted 510 for intellectual property crimes, marking increases of 5.5% and 31.1% year-on-year, respectively, indicating a significant expansion in case handling [1]. - The scope of cases handled includes not only high-tech sectors like new energy but also covers public interest areas such as counterfeit educational materials, seeds, and geographical indication products, thereby ensuring comprehensive protection of various intellectual property rights [1]. Group 2: Legal and Enforcement Mechanisms - The prosecutorial authorities are utilizing digital prosecution methods, the "two laws connection" platform, and a dual reporting system for criminal cases related to intellectual property to ensure fairness and legality in case handling [1]. - In civil, administrative, and public interest litigation related to intellectual property, Hubei's prosecutorial authorities concluded 161 cases, which is three times the number from the previous year, and have been actively monitoring malicious litigation cases [1]. Group 3: Future Initiatives - In 2024, a special action titled "Service Support Construction Protecting Technological Innovation" will be launched across Hubei's prosecutorial authorities, focusing on comprehensive protection of intellectual property and enhancing the enforcement of laws related to technological innovation [2]. - The initiative will emphasize the prosecution of crimes involving technological innovation and will implement a "one case, four checks" approach to improve the quality and effectiveness of protection for technological innovation [2].

去年6月，快手依托对人工智能技术及自身业务的积极探索，推出了自主研发的视频生成大模型可灵AI。推出以来，可灵AI历经二十余次快速迭代，成为国 产大模型的优秀代表。截至目前，可灵AI全球用户规模突破2200万，累计生成1.68亿个视频及3.44亿张图片素材，获得世界互联网大会"中国互联网企业创新 发展十大典型案例""中国AI年度产品金奖"等多项殊荣。"围绕可灵AI视频生成大模型，快手集团已提交100余件专利申请，同时在全球百余个国家和地区提 交了商标注册申请。"焦娇表示。 知识产权是激励创新的催化剂、经济发展的加速器。焦娇指出，在服务人工智能等战略性新兴产业发展方面，知识产权将发挥重要的制度供给和技术供给作 用；同时，人工智能的广泛应用，也将有效赋能知识产权全链条工作，促进知识产权事业高质量发展。最后，焦娇代表快手发出行业倡议，呼吁以人工智能 为代表的广大战略性新兴产业创新主体，全面加强知识产权保护和运用，积极促进行业健康发展，共同迎接人工智能时代的机遇与挑战，助力我国科技跨越 发展、产业优化升级、生产力整体跃升。 据了解，在4.26世界知识产权日期间，快手围绕"保护知识产权 奏响创新乐章"的主题，举办了形式多 ...

Group 1 - The chemical new materials industry in China plays a crucial supporting role in the development of emerging industries such as electronic information, new energy vehicles, and medical services, but there is insufficient self-sufficiency in high-end fields [1] - Experts at the forum emphasized the urgent need for technological innovation and domestic breakthroughs in key materials, particularly in electronic materials and related fields, such as thermal conductive materials and electromagnetic shielding materials for communication, as well as photoresists and masks for semiconductors [1] - The market scale advantage will further manifest during the 14th Five-Year Plan period, especially with the demand for high-end electronic materials driven by emerging fields and consumption upgrades, providing broad space for sustainable industry development [1] Group 2 - In the medical field, chemical materials are essential, but the self-sufficiency rate in high-end markets is low, with over 60% of high-end medical materials being imported [2] - Companies are encouraged to increase R&D investment, promote deep integration of industry, academia, and research, optimize industrial chain layout, and enhance clinical validation to improve the performance and quality of domestic materials [2] - Knowledge property rights are essential for technological innovation, and companies are advised to enhance patent quality, strengthen intellectual property protection, and improve capabilities to handle and resolve intellectual property disputes [2]

去年以来，最高检指导上海、浙江、广东等地办理了一批涉人工智能、芯片制造、动力电池等在创新密 集型领域有重大影响的案件和新类型案件。北京大成（上海）律师事务所合伙人张玲表示，知识产权保 护是推进新质生产力实现质的飞跃的关键。加强知识产权司法保护，就是通过保护创新者的合法权益以 及经济利益，从源头上增强创新供给能力，为优质技术、资本和人才集聚营造良好法治环境，促进科技 创新成果从样品变成产品，推动产业迈向高端化、智能化、绿色化。 为更好激发科技创新内生动力，检察机关不断创新服务举措，通过制发社会治理检察建议、设立检察服 务工作站等方式，护航科技创新。广东检察机关加大对职务科技成果的刑事保护力度，促进科研成果的 高质量转化和产业化发展。湖北检察机关立足当地产业特色与区位优势，通过加强监督办案、健全制度 机制、培育特色品牌等方式激活科技创新策源功能，服务区域性创新高地建设。 保护力度不断增强 "侵犯知识产权类案件类型相对集中，共同犯罪特征明显。"最高人民检察院党组成员、副检察长宫鸣介 绍，2024年检察机关受理审查起诉侵犯商标权类犯罪占比81%，侵犯著作权类犯罪和侵犯商业秘密类犯 罪数量持续增加、增幅较大，侵犯商标权 ...

Group 1 - Yunnan Energy Investment Co., Ltd. announced that its wholly-owned subsidiaries obtained 4 utility model patents and 2 design patents from the National Intellectual Property Administration [1] - The acquisition of these patents is not expected to have a significant impact on the company's financial status or operating results for the current year, but it will enhance the company's intellectual property protection system and promote technological innovation [1] - The company emphasizes the importance of cautious decision-making for investors [1] Group 2 - The company provided a entrusted loan of RMB 1.47 million to its associate company, Tianmeng Company, which has now overdue [4] - The overdue loan amount is relatively small compared to the company's net assets and net profit, and the company has fully provisioned for bad debts, indicating minimal impact on current or future profits [4][7] - The company is taking measures to protect its legal rights, including the possibility of applying for bankruptcy liquidation of Tianmeng Company [4][8] Group 3 - The entrusted loan was initially provided to alleviate Tianmeng Company's financial pressure and support its business expansion, with a loan term from November 26, 2013, to November 24, 2015 [5][6] - Tianmeng Company has been facing severe financial difficulties due to market competition, leading to the suspension of its salt production facility in Laos [6][7] - The company has been actively pursuing debt recovery and exploring options such as debt-to-equity swaps, asset restructuring, and liquidation, but has not reached an agreement with other stakeholders [6][7]

Core Viewpoint - Moleculin Biotech, Inc. has received two additional U.S. patents for Annamycin, enhancing its intellectual property portfolio and exclusivity for this novel drug candidate targeting hard-to-treat cancers and viruses [1][3]. Patent and Intellectual Property - The U.S. Patent and Trademark Office granted U.S. patent number 12,257,261 for the preparation of preliposomal Annamycin lyophilizate and U.S. patent 12,257,262 for the method of reconstituting liposomal Annamycin, both extending the patent term until June 2040 [1]. - With these new patents, the total number of U.S. patents related to Annamycin has increased to four, in addition to European patents granted [3]. Drug Development and Clinical Trials - Annamycin is being developed as a treatment for acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases (STS lung mets), with potential applications for other cancer types based on preclinical studies [2][4]. - The company is conducting the pivotal, adaptive Phase 3 MIRACLE trial evaluating Annamycin in combination with cytarabine for relapsed or refractory AML, with initial data expected in the second half of 2025 [3][5]. Regulatory Status - Annamycin has received Fast Track Status and Orphan Drug Designation from the FDA for relapsed or refractory AML and STS lung mets, as well as Orphan Drug Designation from the European Medicines Agency [3]. Company Overview - Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses, with Annamycin as its lead program designed to avoid cardiotoxicity associated with current anthracyclines [4].

Core Insights - The Supreme People's Procuratorate has released nine typical cases of intellectual property protection, showcasing the effectiveness of the procuratorial work in this area [1][2] - The cases cover a wide range of fields, including advanced manufacturing, software algorithms, cultural sectors like online literature and intangible cultural heritage, as well as traditional Chinese medicine [1] Group 1: Case Highlights - In the case of "Ningbo Sheng Certain Cultural Media Co., Ltd. copyright infringement dispute series of false litigation supervision," the procuratorial authority strengthened supervision over false litigation, integrating criminal and civil prosecution functions, leading to the correction of erroneous civil judgments and the transfer of criminal clues, resulting in the defendant receiving a criminal sentence [1] - The case involving "Beijing Jun Certain Technology Co., Ltd. and others for commercial secret infringement" saw the procuratorial authority simultaneously review criminal offenses and civil infringement facts, discovering omitted criminal clues related to business information infringement from prior civil judgments, and pursuing prosecution based on comprehensive evidence [1] - The "Zhang Certain and Sun Certain copyright infringement case" represents a new type of digital copyright case, involving numerous works and significant amounts, where the procuratorial authority accurately identified the use of "hotlinking" to disseminate works, infringing on the rights of information network dissemination, and pursued criminal liability for copyright infringement [1] Group 2: New Approaches and Goals - The procuratorial authority continues to explore new pathways for handling online infringement cases, as seen in the "Wu Certain and Shi Certain selling counterfeit registered trademark goods case," which involved online sales of counterfeit traditional Chinese medicine products, emphasizing the collection and examination of electronic evidence and accurately determining charges based on subjective intent and harm [2] - The release of these typical cases aims to provide a more comprehensive and direct demonstration of intellectual property prosecution work, guiding the professional and standardized handling of such cases, and enhancing societal awareness of intellectual property protection [2]